Aclarion, Inc. (NASDAQ:ACON) Short Interest Update

Aclarion, Inc. (NASDAQ:ACON) was the target of a significant decrease in short interest in the month of November. As of November 15th, there was short interest totalling 380,900 shares, a decrease of 11.2% from the October 31st total of 428,800 shares. Currently, 3.8% of the shares of the company are sold short. Based on an average daily volume of 480,800 shares, the short-interest ratio is currently 0.8 days.

Institutional Trading of Aclarion

An institutional investor recently bought a new position in Aclarion stock. Virtu Financial LLC bought a new position in shares of Aclarion, Inc. (NASDAQ:ACON) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 115,183 shares of the company’s stock, valued at approximately $38,000. Virtu Financial LLC owned 1.40% of Aclarion as of its most recent SEC filing. Institutional investors and hedge funds own 7.52% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Ascendiant Capital Markets cut their price objective on Aclarion from $1.50 to $1.30 and set a “buy” rating on the stock in a report on Wednesday.

Aclarion Price Performance

Aclarion stock opened at $0.18 on Friday. Aclarion has a 52 week low of $0.16 and a 52 week high of $7.40. The business’s 50-day moving average price is $0.18 and its 200 day moving average price is $0.24.

Aclarion Company Profile

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software.